Irotin 20 mg/ml (IV Infusion)
40 gm vial: ৳ 2,100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Irinotecan hydrochloride |
| Company | Techno drugs ltd |
Indications
- First-line therapy in combination with 5-Fluorouracil (5-FU) and Leucovorin (LV)
- Metastatic carcinoma of the colon or rectum
- Recurred or progressed disease following initial Fluorouracil-based therapy
Pharmacology
- Derivative of Camptothecin
- Interacts with topoisomerase I
- Prevents religation of single-strand breaks in DNA
Dosage & Administration
- Intravenous infusion over 90 minutes
- Intravenous bolus infusion
- Intravenous infusion over 2 hours
- Intravenous infusion over 22 hours
- Weekly dosing
- Once-every-3-week-dosage schedule
- Dosing based on body surface area (mg/m2)
Interaction
- Risk of dehydration with diuretics
- Enhanced lymphocytopenia with prophylactic dexamethasone
- Increased incidence of akathisia with prochlorperazine
- Risk of myelosuppression and diarrhea with antineoplastic agents
- Reduction in irinotecan exposure with St John's wort and ketoconazole
Contraindications
- Known hypersensitivity to the drug or its excipients
Side Effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Constipation
- Anorexia
- Mucositis
- Neutropenia
- Leukopenia
- Anemia
- Thrombocytopenia
- Asthenia
- Pain
- Fever
- Infection
- Abnormal bilirubin
- Alopecia
Pregnancy & Lactation
- Pregnancy category D
- Potential fetal harm
- Excretion in rat milk
Precautions & Warnings
- Cholinergic symptoms
- Early and late diarrhea
- Cholinergic reactions
- Myelosuppression
- Neutropenic fever
- Risk in patients with reduced UGT1A1 activity
- Febrile neutropenia
- Antibiotic support for febrile neutropenia
- Use in pediatric patients not established
- Closer monitoring in geriatric patients
- Recommended starting dose for patients 70 years and older
- Use caution in patients with impaired renal function
- Diminished clearance in hepatic impairment
- Increased exposure to active metabolite SN-38 in hepatic impairment
Use in Special Populations
- Effectiveness not established in pediatric patients
- Closer monitoring in patients over 65 years
- Caution in patients with impaired renal function
- Diminished clearance in hepatic impairment
- Increased exposure to active metabolite SN-38 in hepatic impairment
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Controlled room temperature 15°C to 30°C
- Protection from light
- Storage in carton until time of use